Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384238 | 0.92 | CHRNA7 (0.46) | MAPTHRH3KCNH2KMT2ACYP2D6 | |
| SCHEMBL282864 | 0.85 | — | — | |
| SCHEMBL20346243 | 0.83 | HRH3 (0.44) | MAPTHRH3KCNH2CYP2D6 | |
| SCHEMBL11506629 | 0.80 | HRH3 (0.49) | HRH3KCNH2CYP2D6ALDH1A1 | |
| SCHEMBL21733058 | 0.79 | MAPT (0.46) | MAPTHRH3KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20346244 | 0.79 | HRH3 (0.52) | HRH3KCNH2CYP2D6 | |
| SCHEMBL22155659 | 0.79 | HRH3 (0.42) | HRH3KCNH2CYP2D6 | |
| SCHEMBL23323954 | 0.79 | MAPT (0.42) | MAPTHRH3KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL26680011 | 0.78 | HRH3 (0.66) | HRH3KCNH2CYP2D6ALDH1A1 | |
| SCHEMBL2846986 | 0.78 | HRH3 (0.60) | HRH3KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180186791-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186790-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186790-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | MAPT 2554/4885HRH3 1828/4885KCNH2 2790/4885 |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | MAPT 1938/4885HRH3 1469/4885KCNH2 3788/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | MAPT 4432/4885HRH3 141/4885KCNH2 1654/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | MAPT 4432/4885HRH3 141/4885KCNH2 1654/4885 |
| US-20180186790-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | MAPT 2011/4885HRH3 203/4885KCNH2 3885/4885 |
| US-20180186791-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | MAPT 1695/4885HRH3 1026/4885KCNH2 3402/4885 |
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | MAPT 2183/4885HRH3 1340/4885KCNH2 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.